These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 12731043

  • 1. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
    Meazza R, Comes A, Orengo AM, Ferrini S, Accolla RS.
    Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
    [Abstract] [Full Text] [Related]

  • 2. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L, Castellani P, Meazza R, Tosi G, De Lerma Barbaro A, Procopio FA, Comes A, Zardi L, Ferrini S, Accolla RS.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [Abstract] [Full Text] [Related]

  • 3. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
    Mortara L, Frangione V, Castellani P, De Lerma Barbaro A, Accolla RS.
    Int Immunol; 2009 Jun 01; 21(6):655-65. PubMed ID: 19395374
    [Abstract] [Full Text] [Related]

  • 4. New strategies of mammary cancer vaccination.
    Accolla RS, Frangione V, De Lerma Barbaro A, Mortara L.
    Breast J; 2010 Jun 01; 16 Suppl 1():S42-4. PubMed ID: 21050309
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
    Ekkirala CR, Cappello P, Accolla RS, Giovarelli M, Romero I, Garrido C, Garcia-Lora AM, Novelli F.
    Pancreas; 2014 Oct 01; 43(7):1066-72. PubMed ID: 24987872
    [Abstract] [Full Text] [Related]

  • 8. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
    Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S.
    Cancer Res; 2006 Jan 15; 66(2):1147-54. PubMed ID: 16424052
    [Abstract] [Full Text] [Related]

  • 9. Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
    Frey AB.
    J Immunol; 1995 May 01; 154(9):4613-22. PubMed ID: 7722313
    [Abstract] [Full Text] [Related]

  • 10. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
    Marzo AL, Lake RA, Robinson BW, Scott B.
    Cancer Res; 1999 Mar 01; 59(5):1071-9. PubMed ID: 10070965
    [Abstract] [Full Text] [Related]

  • 11. Comparison of Abeta(b-/-), H2-DM(-), and CIITA(-/-) in second-set skin allograft rejection.
    Felix NJ, de Serres S, Meyer AA, Ting JP.
    J Surg Res; 2002 Feb 01; 102(2):185-92. PubMed ID: 11796017
    [Abstract] [Full Text] [Related]

  • 12. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.
    Martin BK, Frelinger JG, Ting JP.
    J Immunol; 1999 Jun 01; 162(11):6663-70. PubMed ID: 10352284
    [Abstract] [Full Text] [Related]

  • 13. A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites.
    Arancibia-Cárcamo CV, Osawa H, Arnett HA, Háskova Z, George AJ, Ono SJ, Ting JP, Streilein JW.
    Eur J Immunol; 2004 Feb 01; 34(2):471-80. PubMed ID: 14768052
    [Abstract] [Full Text] [Related]

  • 14. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
    Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, Favre G, Couderc B.
    Cancer Gene Ther; 2000 Dec 01; 7(12):1543-56. PubMed ID: 11228533
    [Abstract] [Full Text] [Related]

  • 15. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.
    Itoh-Lindstrom Y, Piskurich JF, Felix NJ, Wang Y, Brickey WJ, Platt JL, Koller BH, Ting JP.
    J Immunol; 1999 Sep 01; 163(5):2425-31. PubMed ID: 10452977
    [Abstract] [Full Text] [Related]

  • 16. Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer.
    Mortara L, Giuliani L, De Lerma Barbaro A, Accolla RS, Noonan DM.
    Surg Oncol; 2007 Dec 01; 16 Suppl 1():S33-6. PubMed ID: 18035537
    [Abstract] [Full Text] [Related]

  • 17. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE, Su FW, Atherton JM, Allison JP.
    Cancer Res; 1994 Dec 15; 54(24):6477-83. PubMed ID: 7527298
    [Abstract] [Full Text] [Related]

  • 18. Fibrosarcoma cells expressing allogeneic MHC Class II antigens induce protective antitumor immunity.
    Leach DR, Callahan GN.
    J Immunol; 1995 Jan 15; 154(2):738-43. PubMed ID: 7814880
    [Abstract] [Full Text] [Related]

  • 19. Rejection of mouse sarcoma cells after transfection of MHC class II genes.
    Ostrand-Rosenberg S, Thakur A, Clements V.
    J Immunol; 1990 May 15; 144(10):4068-71. PubMed ID: 2332639
    [Abstract] [Full Text] [Related]

  • 20. Correction of defective expression in MHC class II deficiency (bare lymphocyte syndrome) cells by retroviral transduction of CIITA.
    Bradley MB, Fernandez JM, Ungers G, Diaz-Barrientos T, Steimle V, Mach B, O'Reilly R, Lee JS.
    J Immunol; 1997 Aug 01; 159(3):1086-95. PubMed ID: 9233601
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.